Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBDS's Cash-to-Debt is ranked higher than
90% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. CBDS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBDS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: No Debt
0.05
No Debt
Equity-to-Asset 0.39
CBDS's Equity-to-Asset is ranked lower than
69% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. CBDS: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
CBDS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1203.89  Med: 0.24 Max: 0.94
Current: 0.39
-1203.89
0.94
Piotroski F-Score: 5
Altman Z-Score: 5.71
Beneish M-Score: 28.40
WACC vs ROIC
54.15%
-101.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -863.64
CBDS's Operating Margin % is ranked lower than
95% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. CBDS: -863.64 )
Ranked among companies with meaningful Operating Margin % only.
CBDS' s Operating Margin % Range Over the Past 10 Years
Min: -81527.27  Med: -25.66 Max: 1.76
Current: -863.64
-81527.27
1.76
Net Margin % -921.75
CBDS's Net Margin % is ranked lower than
95% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. CBDS: -921.75 )
Ranked among companies with meaningful Net Margin % only.
CBDS' s Net Margin % Range Over the Past 10 Years
Min: -205285.71  Med: -28.95 Max: 1.32
Current: -921.75
-205285.71
1.32
ROE % -157.65
CBDS's ROE % is ranked lower than
95% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. CBDS: -157.65 )
Ranked among companies with meaningful ROE % only.
CBDS' s ROE % Range Over the Past 10 Years
Min: -837  Med: -126.67 Max: 6.12
Current: -157.65
-837
6.12
ROA % -80.76
CBDS's ROA % is ranked lower than
94% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. CBDS: -80.76 )
Ranked among companies with meaningful ROA % only.
CBDS' s ROA % Range Over the Past 10 Years
Min: -775.08  Med: -96.55 Max: 3.7
Current: -80.76
-775.08
3.7
ROC (Joel Greenblatt) % -61215.69
CBDS's ROC (Joel Greenblatt) % is ranked lower than
100% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. CBDS: -61215.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBDS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -318733.33  Med: -1300 Max: 7.58
Current: -61215.69
-318733.33
7.58
3-Year Revenue Growth Rate 152.00
CBDS's 3-Year Revenue Growth Rate is ranked higher than
99% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. CBDS: 152.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBDS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -79.5 Max: 152
Current: 152
0
152
3-Year EBITDA Growth Rate 31.50
CBDS's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. CBDS: 31.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBDS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 31.5
Current: 31.5
0
31.5
3-Year EPS without NRI Growth Rate 30.70
CBDS's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. CBDS: 30.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBDS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -166.8 Max: 30.7
Current: 30.7
0
30.7
GuruFocus has detected 3 Warning Signs with Cannabis Sativa Inc CBDS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBDS's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:CBDS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2833
Compare:TSE:7523, HKSE:08082, OSTO:ATIC, OCSE:SFG, ASX:TNK, TSE:6039, ASX:NVL, TSE:2344, TSE:9731, HKSE:08358, TSE:4656, OHEL:FONDIA, ASX:SHJ, ASX:AHX, LSE:KEYS, TSE:3685, TSE:6186, TSE:4696, TSE:6537, HKSE:00922 » details
Traded in other countries:9C4.Germany,
Headquarter Location:USA
Cannabis Sativa Inc and its subsidiary are engaged in research, development and licensing of specialized natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems.

Cannabis Sativa Inc along with its subsidiaries engages in the development and licensing of natural cannabis products. Its product offering includes cannabis formulas, edibles, topicals, strains, recipes and delivery systems under the Go Deep, Go Deep EXTRA (GDX), Face Garden, Body Garden and Lip Garden line of products. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula.

Ratios

vs
industry
vs
history
PB Ratio 52.66
CBDS's PB Ratio is ranked lower than
95% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. CBDS: 52.66 )
Ranked among companies with meaningful PB Ratio only.
CBDS' s PB Ratio Range Over the Past 10 Years
Min: 8.62  Med: 27.49 Max: 750
Current: 52.66
8.62
750
PS Ratio 208.95
CBDS's PS Ratio is ranked lower than
96% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. CBDS: 208.95 )
Ranked among companies with meaningful PS Ratio only.
CBDS' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 50.26 Max: 7790
Current: 208.95
1.76
7790
EV-to-EBIT -21.52
CBDS's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. CBDS: -21.52 )
Ranked among companies with meaningful EV-to-EBIT only.
CBDS' s EV-to-EBIT Range Over the Past 10 Years
Min: -116.7  Med: -15.1 Max: -0.1
Current: -21.52
-116.7
-0.1
EV-to-EBITDA -24.01
CBDS's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. CBDS: -24.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBDS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -994  Med: -13.7 Max: 280
Current: -24.01
-994
280
EV-to-Revenue 218.27
CBDS's EV-to-Revenue is ranked lower than
95% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. CBDS: 218.27 )
Ranked among companies with meaningful EV-to-Revenue only.
CBDS' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 147.7 Max: 4764.1
Current: 218.27
1.9
4764.1
Current Ratio 0.12
CBDS's Current Ratio is ranked lower than
96% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. CBDS: 0.12 )
Ranked among companies with meaningful Current Ratio only.
CBDS' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.33 Max: 6.75
Current: 0.12
0.04
6.75
Quick Ratio 0.11
CBDS's Quick Ratio is ranked lower than
94% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. CBDS: 0.11 )
Ranked among companies with meaningful Quick Ratio only.
CBDS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.3 Max: 6.68
Current: 0.11
0.03
6.68
Days Inventory 15.70
CBDS's Days Inventory is ranked higher than
94% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. CBDS: 15.70 )
Ranked among companies with meaningful Days Inventory only.
CBDS' s Days Inventory Range Over the Past 10 Years
Min: 14.04  Med: 21.33 Max: 2007.5
Current: 15.7
14.04
2007.5
Days Sales Outstanding 4.15
CBDS's Days Sales Outstanding is ranked higher than
99% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. CBDS: 4.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBDS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.15  Med: 21.18 Max: 37.76
Current: 4.15
4.15
37.76
Days Payable 316.79
CBDS's Days Payable is ranked higher than
85% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. CBDS: 316.79 )
Ranked among companies with meaningful Days Payable only.
CBDS' s Days Payable Range Over the Past 10 Years
Min: 78.21  Med: 234.64 Max: 88147.5
Current: 316.79
78.21
88147.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.20
CBDS's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. CBDS: -11.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBDS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -135.5  Med: -33.6 Max: 0
Current: -11.2
-135.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 4.15
CBDS's Price-to-Median-PS-Value is ranked lower than
92% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. CBDS: 4.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBDS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.21 Max: 118.4
Current: 4.15
0.11
118.4
Earnings Yield (Greenblatt) % -4.66
CBDS's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. CBDS: -4.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBDS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1185.7  Med: -6.6 Max: -0.9
Current: -4.66
-1185.7
-0.9

More Statistics

Revenue (TTM) (Mil) $0.62
EPS (TTM) $ -0.27
Beta8.53
Volatility97.65%
52-Week Range $1.92 - 9.74
Shares Outstanding (Mil)21.17

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}